Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

How can I start contributing?

Getting started is easy! Here are a few good-to-know tips, that will help you navigate the different aspects of the EHA Hub.

Read more

Participation grants & abstract awards

Participation grants
The call for participation grant applications has closed on March 1, 2021 (23:59 CET). Participation grant application has closed

Participation Grants (previously called Travel Grants) provide complimentary registration for the upcoming EHA Virtual Congress.

Read more

Abstract & Case Report submission

Late-breaking case report submission is now closed.

Read more

EHA Research Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Travel Grants

Travel grant application is now closed 

Travel grants are intended to support young investigators in the region; therefore, applicants should be 40 years of age or young, and are reserved for applicants from Armenia, Georgia, Iran, Azerbaijan, and Türkiye.

Read more

EHA reaffirms commitment to hematology's future with new brand identity

The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.

Read more